pegylated interferon

ApprovedSmall molecule

Merck & Co.

pegylated interferon is one of 246 small molecule programs targeting Insulin resistance. It is currently in Approved.

Indications

Total Trials

Active Trials

245

Competitors

Pipeline

Status by Indication[3][1]

Indication

Insulin ResistanceActive, not recruiting

Liver TransplantActive, not recruiting

Chronic HepatitisActive, not recruiting

Multiple MyelomaActive, not recruiting

Chronic Lymphocytic LeukemiaActive, not recruiting

Hepatitis BActive, not recruiting

Hepatitis CActive, not recruiting

Hepatitis C Virus InfectionActive, not recruiting

Insulin ResistancePreclinical

Active, not recruiting

Liver TransplantApproved

Active, not recruiting

Chronic HepatitisPhase 2

Active, not recruiting

Multiple MyelomaPhase 2

Active, not recruiting

Chronic Lymphocytic LeukemiaPhase 1/Phase 2

Active, not recruiting

Hepatitis BPhase 1

Active, not recruiting

Hepatitis CPhase 3

Active, not recruiting

Hepatitis C Virus InfectionApproved

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

pegylated interferon

Merck & Co.

Approved

1 2

Ninlaro

Takeda

Preclinical

18 3

Prolia

Amgen

Preclinical

5 4

Eliquis

Bristol-Myers Squibb

Preclinical

3 5

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 6

Adriamycin

GGynecologic Oncology Group

Preclinical

9 7

Nolvadex

AstraZeneca

Preclinical

1 8

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 9

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 10

Abecma

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Hepatitis12 trials

Role of Heme Oxygenase in the Pathogenesis of Hepatocellular Injury in Chronic Hepatitis C Virus (HCV) Infection

Unknown status·—·N/A·NCT00842205·150 enrolled

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Completed· AbbVie logo

AbbVie·Phase 2·NCT00851890·30 enrolled

A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00943761·45 enrolled

Show 9 more trials

A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B

Completed·SShanghai HEP Pharmaceutical Co., Ltd.·Phase 2·NCT04426968·96 enrolled

Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT01525628·72 enrolled

Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501

Completed· Eisai logo

Eisai·Phase 2·NCT01355289·65 enrolled

A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00880763·90 enrolled

Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT01852604·143 enrolled

Different Regimens of Pegylated Interferon and Lamivudine Combination Therapy in Chronic Hepatitis B Patients

Completed·—·Phase 2·NCT00226447·30 enrolled

Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B

Completed·RReplicor Inc.·Phase 2·NCT02726789·5 enrolled

A Real-World Study of Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis B

Unknown status·TTongji Hospital·Phase 4·NCT03357822·2,000 enrolled

Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00120861

Hepatitis C10 trials

Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders

Completed·CConatus Pharmaceuticals Inc.·Phase 2·NCT01051921·67 enrolled

Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C

Approved for marketing· Gilead logo

Gilead··NCT01779518

Pegylated Interferon Therapy for Acute Hepatitis C Infection in HIV-infected Patients

Completed·UUniversity Hospital, Bonn·Phase 4·NCT00132210·200 enrolled

Show 7 more trials

Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders

Terminated·CConatus Pharmaceuticals Inc.·Phase 2·NCT01273064·114 enrolled

Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects

Completed· AbbVie logo

AbbVie·Phase 2·NCT01314261·37 enrolled

Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00704405·285 enrolled

A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01290731·49 enrolled

HEPMET-1: Evaluate the Feasibility, Mental Sideeffects and the Efficacy of Hepatitis C Treatment in a MMT Group.

Completed·SSorlandet Hospital HF·Phase 3·NCT00147784·10 enrolled

Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C

Completed· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT00120835

The Effect of Adding Metformin to the Treatment of Hepatitis C

Completed·TTehran University of Medical Sciences·Phase 4·NCT00560690·140 enrolled

Multiple Myeloma1 trial

A Phase II Trial Comparing the Quality of Life, Tolerability and Toxicity of PEG Intron With INTRON® A in Patients With Multiple Myeloma

Completed·RRoyal Marsden NHS Foundation Trust·Phase 2·NCT00323505

Liver1 trial

Antiviral & Antifibrotic Liver Therapy in HCV + Drinkers and Non-Drinkers

Completed·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT00211848·207 enrolled

Hepatitis C Virus Infection1 trial

Treatment of Acute Hepatitis C Virus Infection With Pegylated Interferon in Injection Drug Users

Completed·NNational Institute on Drug Abuse (NIDA)·Phase 4·NCT00194480·21 enrolled

6 more indications

Insulin resistance1 trial

Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562)

Completed· Merck & Co. logo

Merck & Co.··NCT00705224·250 enrolled

Chronic Lymphocytic Leukemia1 trial

Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia

Withdrawn·MM.D. Anderson Cancer Center·Phase 1/2·NCT00962715

Treatment1 trial

Pilot Trial of Bavituximab Combined With Ribavirin for Initial Treatment of Chronic HepC Virus Genotype 1 Infection

Completed·PPeregrine Pharmaceuticals·Phase 1/2·NCT01273948·66 enrolled

Liver Transplant1 trial

Orthotopic Liver Transplant (OLT) Recipients With Hepatitis C Virus (HCV) Under Preemptive Treatment

Withdrawn·TThe University of Texas Health Science Center, Houston·Phase 4·NCT00167557

Trial1 trial

Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients

Withdrawn· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT01858961

Hepatitis B1 trial

Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02259855·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 31 trial records for pegylated interferon. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — pegylated interferon compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for pegylated interferon. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Merck & Co.

pegylated interferon

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Hepatitis12 trials

Hepatitis C10 trials

Multiple Myeloma1 trial

Liver1 trial

Hepatitis C Virus Infection1 trial

Insulin resistance1 trial

Chronic Lymphocytic Leukemia1 trial

Treatment1 trial

Liver Transplant1 trial

Trial1 trial

Hepatitis B1 trial

References

Drug Info

Quick Facts

Related News